ABSTRACT Introduction: Infections caused by methicillin-resistant Staphylococcus aureus (MRSA) have become common in hospitals and the community environment, and this wide resistance has limited patient treatment. Clindamycin (CL) represents an important alternative therapy for infections caused by S. aureus. Antimicrobial susceptibility testing using standard methods may not detect inducible CL resistance. This study was performed to detect the phenotypes of resistance to macrolides-lincosamides-streptogramin B (MLS B ) antibiotics, including CL, in clinical samples of S. aureus from patients at a tertiary hospital in Santa Maria, State of Rio Grande do Sul, Brazil. Methods: One hundred and forty clinical isolates were submitted to the disk diffusion induction test (D-test) with an erythromycin (ER) disk positioned at a distance of 20mm from a CL disk. The results were interpreted according to the recommendations of the Clinical and Laboratory Standards Institute (CLSI). Results: In this study, 29 (20.7%) of the 140 S. aureus samples were resistant to methicillin (MRSA), and 111 (79.3%) were susceptible to methicillin (MSSA). The constitutive resistance phenotype (cMLS B ) was observed in 20 (14.3%) MRSA samples and in 5 (3.6%) MSSA samples, whereas the inducible resistance phenotype (iMLS B ) was observed in 3 (2.1%) MRSA samples and in 8 (5.8%) MSSA samples. Conclusions: The D-test is essential for detecting the iMLS B phenotype because the early identifi cation of this phenotype allows clinicians to choose an appropriate treatment for patients. Furthermore, this test is simple, easy to perform and inexpensive.
INTRODUCTION

1
. The clinical importance of S. aureus has grown particularly because of the increased occurrence of serious infections caused by methicillin-resistant S. aureus (MRSA) 2 , which are among the most frequent bacteria in healthcare-associated infections (HAIs) 3 .
Changes in susceptibility patterns to β-lactam antibiotics have led to a renewed interest in the use of macrolideslincosamides-streptogramin B (MLS B ) 4 antibiotics. Clindamycin (CL) is the preferred agent for the treatment of MRSA due to its excellent pharmacokinetic properties, such as optimal tissue penetration and accumulation in abscesses 5, 6 . Furthermore, CL is a frequent choice for treating staphylococcal infections because this antibiotic can be orally administered and is well tolerated 7, 8 . However, the indiscriminate use of MLS B antibiotics has led to an increase in the number of Staphylococcus spp. isolates that are resistant to these drugs 9 .
MLS B antimicrobials are structurally unrelated; however, these drugs are microbiologically related because of their similar modes of action. These drugs inhibit bacterial protein synthesis in susceptible organisms by reversibly binding to the 23S ribosomal ribonucleic acid (rRNA) receptor of the 50S ribosomal subunit 10 . The strains were stored in tryptone soya broth, which contained glycerol 15%, at -80°C. The strains were kept in the Bacterial Collection of the Bacteriology Laboratory of the Department of Clinical and Toxicological Analyses at the Federal University of Santa Maria (UFSM).
All of the collected isolates were submitted to antimicrobial susceptibility testing using the D-test (Kirby-Bauer) to classify the strains as susceptible, intermediate or resistant to cefoxitin (CFO, 30µg) (Sensidisc ®, BD Diagnostics, New Jersey, USA); CL (2µg) (Sensidisc ® , BD Diagnostics, New Jersey, USA ) and ER (15µg) (Sensifar ®, Cefar Diagnóstica Ltda, São Paulo, SP, Brasil). S. aureus ATCC 25923 was used as the quality control strain for the discs, as recommended by the CLSI 13 . The strains were inoculated in tryptone soya agar and incubated for 24h in a bacterial incubator (35ºC ± 2ºC). The bacterial inoculum was prepared in a sterile solution, and the turbidity was adjusted to McFarland standard 0.5. The suspensions were inoculated in Mueller-Hinton agar and incubated under the previously described conditions. Oxacillin resistance was detected in the MRSA strains using the CFO discdiffusion method and the oxacillin broth microdilution method 13 with the MicroScan ® automated system (Siemens Healthcare Diagnostics, Deerfi eld, IL, USA).
Strains that were resistant to ER and susceptible to CL were submitted to the D-test to detect inducible CL resistance. The ER disk was placed at a distance of 20mm (center to center) from the CL disk and incubated for a period of 18h 13 . The inhibition zone diameters were interpreted as follows: susceptible (S) ≥ 23mm; intermediate (I) = 14 to 22mm; resistant (R) ≤ 13mm for ER; S ≥ 21mm; I = 15-20mm; R ≤ 14mm for CL; and S ≥ 22mm and R ≤ 21mm for CFO. When the zone diameter of the ER disk was ≤ 13mm, and the diameter of the CL disk was ≥ 21mm and when both zones were circular, the test was considered to be negative for inducible resistance (negative D-test). When the zone diameter of ER disk was ≤ 13mm and the diameter of the CL disk was ≥ 21mm and the inhibition zone around the CL disc was D-shaped, the test was considered to be positive for inducible resistance (positive D-test).
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Of the 140 samples of S. aureus, 29 (20.7%) were identifi ed as MRSA and 111 (79.3%) as methicillin-sensitive Staphylococcus aureus (MSSA). The cMLS B phenotype was observed in 20 (14.3%) MRSA samples, and the iMLS B phenotype was observed in 3 (2.1%) MSSA samples. Additionally, the cMLS B phenotype was found in 5 (3.6%) MSSA samples, whereas the iMLS B phenotype was found in 8 (5.8%) MSSA samples.
Concomitant susceptibility to CL and ER was observed in most (57.9%) of the isolate samples, and this phenotype was predominant in the MSSA samples. Other susceptibility profi les were found in 21 isolates as shown in Table 1 . The clinical samples with S. aureus isolates are described in Table 2 .
Of the 140 samples of S. aureus in this study, 20.7% were MRSA and 79.3% were MSSA. Similar results were obtained in a study conducted in India by Ciraj et al. 10 where in the MRSA prevalence was 17.3%. The relatively low frequency of MRSA in the present study may be due to the work of the Infection Control Hospital Committee, which has been developing measures to control the use of antibiotics and to implement proper hygienization practices by the hospital staff of HUSM since 2006.
The iMLS B phenotype was found in 3 (10.3%) of the 29 MRSA samples and in 8 (7.2%) of the 111 MSSA samples. Our results confi rm the fi ndings in the study by Juyal et al. 11 in which a higher frequency of the iMLS B phenotype was found in MRSA strains (19.4%) than in MSSA strains (6.3%).
However, the study by Amorim et al. 14 at Marília Medical School Hospitals in State of São Paulo, Brazil and the study by Eksi et al. 15 at Gaziantep University Hospital in Turkey indicated a higher prevalence of the iMLS B phenotype in MSSA strains. The incidence of this phenotype in S. aureus varies according to the population of patients studied, geographic region, hospital characteristics and susceptibility or resistance to methicillin 8, 16 .
In the present study, we found a higher prevalence of the cMLS B phenotype in the MRSA strains (20/29; 68.9%) compared with the MSSA strains (5/111; 4.5%). In addition, other authors have found a higher frequency of constitutive resistance in MRSA isolates. Prabhu et al. 17 Among the clinical samples of S. aureus, the iMLS B phenotype was identifi ed more frequently in general secretions, peripheral blood, urine andbody fl uids.
In this study, we found a higher frequency of the cMLS B and iMLS B phenotypes in MRSA strains. Therefore, the D-test is essential for monitoring susceptibility to CL and should be included in routine antimicrobial susceptibility testing because the inducible resistance phenotype can inhibit the action of CL, thereby rendering treatment ineffective. In addition, decisions regarding the method for routinely detecting Staphylococcus spp. with the iMLS B phenotype (ER-R/I, CL-S) should be discussed at individual institutions based on local data.
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